PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma?
Status:
Recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
PROACT will establish the effectiveness of the angiotensin-converting enzyme inhibitor (ACEI)
enalapril maleate (enalapril) in preventing cardiotoxicity in patients with breast cancer and
non-Hodgkin lymphoma undergoing adjuvant epirubicin-based chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
South Tees Hospitals NHS Foundation Trust
Collaborators:
Newcastle University Newcastle-upon-Tyne Hospitals NHS Trust University of Durham